| ID | Sequence | Length | GC content |
|---|---|---|---|
| CAGUUAGUACACUGAAAUUCAAAGUCAUGCUCAUAACUGUUAAUGAAAG… | 1246 nt | 0.3876 | |
| CAGUUAGUACACUGAAAUUCAAAGUCAUGCUCAUAACUGUUAAUGAAAG… | 1135 nt | 0.3903 | |
| CAGUUAGUACACUGAAAUUCAAAGUCAUGCUCAUAACUGUUAAUGAAAG… | 1132 nt | 0.3905 | |
| CAGUUAGUACACUGAAAUUCAAAGUCAUGCUCAUAACUGUUAAUGAAAG… | 1129 nt | 0.3906 | |
| CAGUUAGUACACUGAAAUUCAAAGUCAUGCUCAUAACUGUUAAUGAAAG… | 1102 nt | 0.3884 | |
| CAGUUAGUACACUGAAAUUCAAAGUCAUGCUCAUAACUGUUAAUGAAAG… | 1093 nt | 0.3715 | |
| CAGUUAGUACACUGAAAUUCAAAGUCAUGCUCAUAACUGUUAAUGAAAG… | 1054 nt | 0.3890 | |
| CAGUUAGUACACUGAAAUUCAAAGUCAUGCUCAUAACUGUUAAUGAAAG… | 1297 nt | 0.3832 |
This gene encodes a secreted protein belonging to the complement factor H protein family. It binds to Pseudomonas aeruginosa elongation factor Tuf together with plasminogen, which is proteolytically activated. It is proposed that Tuf acts as a virulence factor by acquiring host proteins to the pathogen surface, controlling complement, and facilitating tissue invasion. Mutations in this gene are associated with an increased risk of atypical hemolytic-uremic syndrome. [provided by RefSeq, Oct 2009]
A study in humans identified the CFHR1 as a plasma protein exhibiting large abundance shifts between severe and nonsevere alcohol-associated hepatitis, classifying it as a severity discriminant within a signature useful for diagnostic assessment [Argemi et al. DOI:10.1016/J.Ajpath.2022.08.009].